Sucampo Pharmaceuticals (NASDAQ: SCMP) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Sucampo Pharmaceuticals to related businesses based on the strength of its profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Profitability

This table compares Sucampo Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sucampo Pharmaceuticals -61.99% 56.58% 15.47%
Sucampo Pharmaceuticals Competitors -4,731.98% -352.85% -43.31%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sucampo Pharmaceuticals and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sucampo Pharmaceuticals 0 1 5 0 2.83
Sucampo Pharmaceuticals Competitors 1377 4464 12274 311 2.63

Sucampo Pharmaceuticals currently has a consensus target price of $18.00, suggesting a potential upside of 48.15%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.42%. Given Sucampo Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Sucampo Pharmaceuticals is more favorable than its rivals.

Earnings & Valuation

This table compares Sucampo Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Sucampo Pharmaceuticals $247.08 million $107.68 million -3.69
Sucampo Pharmaceuticals Competitors $464.68 million $167.54 million -6.58

Sucampo Pharmaceuticals’ rivals have higher revenue and earnings than Sucampo Pharmaceuticals. Sucampo Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

55.4% of Sucampo Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.1% of Sucampo Pharmaceuticals shares are owned by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Sucampo Pharmaceuticals has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, Sucampo Pharmaceuticals’ rivals have a beta of 6.57, indicating that their average share price is 557% more volatile than the S&P 500.

Summary

Sucampo Pharmaceuticals beats its rivals on 7 of the 12 factors compared.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.